Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-22,000
Closed -$633K 35
2023
Q4
$633K Buy
22,000
+2,000
+10% +$60.5K 0.07% 34
2023
Q3
$663K Hold
20,000
0.08% 35
2023
Q2
$734K Sell
20,000
-25,000
-56% -$973K 0.09% 34
2023
Q1
$1.84M Buy
+45,000
New +$1.94M 0.22% 29
2022
Q4
Sell
-2,500
Closed -$589K 53
2022
Q3
$589K Sell
2,500
-12,500
-83% -$607K 0.08% 39
2022
Q2
$786K Sell
15,000
-5,000
-25% -$255K 0.1% 40
2022
Q1
$1.04M Buy
+20,000
New +$1.04M 0.12% 36
2021
Q4
Sell
-20,000
Closed -$860K 50
2021
Q3
$860K Buy
+20,000
New +$886K 0.12% 37
2021
Q2
Sell
-20,000
Closed -$725K 44
2021
Q1
$725K Buy
+20,000
New +$710K 0.12% 29
2020
Q4
Sell
-21,080
Closed -$734K 47
2020
Q3
$734K Buy
21,080
+3,162
+18% +$111K 0.17% 29
2020
Q2
$556K Buy
+17,918
New +$609K 0.14% 28

Other funds holding PFE

Criteria Caixa's PFE Position: Q4 2025 in Review

Criteria Caixa sold out of Pfizer (PFE) in Q4 2025, closing a stake of 1,805,855 shares — an estimated $46M sold.

Criteria Caixa first reported a position in PFE in Q4 2019 and held it in 24 quarters. The position peaked at $71.6M in Q4 2021. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Criteria Caixa reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Criteria Caixa sold 1,805,855 Pfizer shares in Q4 2025, an estimated $46M.
  • Criteria Caixa first reported a position in Pfizer in Q4 2019 and held it in 24 quarters.
  • Criteria Caixa's Pfizer position peaked at $71.6M in Q4 2021.
  • 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Criteria Caixa's 13F filing for Q4 2025, filed 17 Feb 2026.